Extent Research Assistant ×
📩 [email protected] | 📞 +1 (212) 951-1369

Request Sample/Pricing Details:

💬
Extent Research Global Chimeric Antigen Receptor Cell Therapy Market
REPORT DETAILS FREE ANALYSIS INQUIRY FOR BUYING REQUEST SAMPLE
REPORT DETAILS FREE ANALYSIS INQUIRY FOR BUYING REQUEST SAMPLE
Home / Medical Care / Global Chimeric Antigen Receptor Cell Therapy Market

Global Chimeric Antigen Receptor Cell Therapy Market

Comprehensive industry overview, market size, share, trends, and forecast analysis.

Medical Care Oct 2022 Global 350 Pages No of Tables: 220 No of Figures: 60 Reviewed By: Priya M Author: Julie
Buy Now Free Analysis
Request for TOC Speak to Analyst Inquire Before Buying Download Free Sample PDF

Global Chimeric Antigen Receptor Cell Therapy Market

Market Size in USD Billion

CAGR : 17.60%
USD 1.14
2025
USD 4.17
2033
Forecast Period 2025 - 2033
Market Size (Base Year) USD 1.14 Billion
Market Size (Forecast) USD 4.17 Billion
CAGR 17.60%
Major Market Players Data provided in full report

EXTENT RESEARCH published the latest report on global Chimeric Antigen Receptor Cell Therapy Market with the goal of offering the complete market statistics and analytics to the readers all under a single roof. This report covers in-depth knowledge regarding the qualitative and quantitative market study to help clients gain a better understanding of the future market position. Global Chimeric Antigen Receptor Cell Therapy market report primarily provides evidences which are responsible for the significant growth of the market. These evidences include market dynamics, consumer behavior, growth stimulators, geographical distribution, and competitive landscape. The geographical segment analysis sheds light on the regional & environmental impact on the market as well as the position of the market on both the regional and global platform in terms of finance and product popularity.

Data provided by Extent Research. Source: https://www.extentresearch.com/chimeric-antigen-receptor-cell-therapy-market

Segmentation of the Global Chimeric Antigen Receptor Cell Therapy Market:

By Type

  • Monotherapy, Combination Therapy,

By Application

  • Acute Leukemia, Non-hodgkin’s Lymphoma, Multiple Myeloma, Transplant Rejection, Other,

Some of the regions exhibiting a distinct growth platform for the global Chimeric Antigen Receptor Cell Therapy market includes:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, South-East Asia, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa

Most importantly, the report represents all the financial and market analytics to offer a better insight on the market status and profitable gains during the forecast period. Furthermore, the detailed study on the competitive landscape is a mirror view of the markets future expansions among the key market participants. The market research facts such as sales & marketing, distribution, new product launches, latest manufacturing trends, and financial gains are also well mentioned the Chimeric Antigen Receptor Cell Therapy market report. The key market players dominating the global Chimeric Antigen Receptor Cell Therapy market includes: Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc, Guangzhou Anjie Biomedical Technology Co Ltd, Hangzhou Converd Co Ltd, Hebei Senlang Biotechnology Inc Ltd, HRAIN Biotechnology Co Ltd, Juno Therapeutics Inc, Kite Pharma Inc, Nanjing Legend Biotech Co Ltd, NantKwest Inc, Nkarta Inc, Novartis AG, Ono Pharmaceutical Co Ltd, Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, Sorrento Therapeutics Inc, Takara Bio Inc, .

In the conclusion, the global Chimeric Antigen Receptor Cell Therapy market report includes certain market facts such as opportunities & challenges, regional analysis, competitive landscape study, latest market trends, market size, share, revenue, market dynamics, and forecast details. At, Extent Research, we ensure that all the global Chimeric Antigen Receptor Cell Therapy market related details is provided to the readers for helping them reach their business growth targets through the smart thinking.

Report Scope and Market Segmentation

ATTRIBUTES Global Chimeric Antigen Receptor Cell Therapy Market KEY MARKET INSIGHTS
Segments Covered
  • By Product Type: All Products Type Includes
  • By Application: All Application Type Includes
  • By End User: All End User Type Includes
  • By Distribution Channel: All Distribution Channel Includes
Countries Covered
  • North America
    • U.S., Canada, Mexico
  • Europe
    • Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe
  • Asia-Pacific
    • China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific
  • Latin America
    • Brazil, Argentina, Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players
  • Leading Tier 1 Corporations
  • Prominent Regional Manufacturers
  • Emerging Market Disruptors
  • Technology Integrators & Suppliers
  • *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities
  • Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability.
  • Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands.
  • Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities.
  • Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry.
  • Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...
Read more about Julie
Priya M

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...
Learn more about Priya M

Industry Related Reports

Smart Diapers Market Advance Directive Market DKK-1 Biomarker Market Global Anti Hepatitis Virus Drugs Market Global Mecobalamin Market Global Intraoperative Monitoring (IOM) Solutions Market
BASIC ATTRIBUTES | KEY MARKET INSIGHTS
Report Title Global Chimeric Antigen Receptor Cell Therapy Market
Base Year 2025
Forecast Period 2025 - 2033
Market Size (Base) USD 1.14 Billion
Projected Size USD 4.17 Billion
CAGR 17.60%

Table of Contents

1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Chimeric Antigen Receptor Cell Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2035 1.2.2 Monotherapy 1.2.3 Combination Therapy 1.3 Market by Application 1.3.1 Global Chimeric Antigen Receptor Cell Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2035 1.3.2 Acute Leukemia 1.3.3 Non-hodgkin's Lymphoma 1.3.4 Multiple Myeloma 1.3.5 Transplant Rejection 1.3.6 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Chimeric Antigen Receptor Cell Therapy Market Perspective (2017-2035) 2.2 Chimeric Antigen Receptor Cell Therapy Growth Trends by Region 2.2.1 Chimeric Antigen Receptor Cell Therapy Market Size by Region: 2017 VS 2021 VS 2035 2.2.2 Chimeric Antigen Receptor Cell Therapy Historic Market Size by Region (2017-2022) 2.2.3 Chimeric Antigen Receptor Cell Therapy Forecasted Market Size by Region (2023-2035) 2.3 Chimeric Antigen Receptor Cell Therapy Market Dynamics 2.3.1 Chimeric Antigen Receptor Cell Therapy Industry Trends 2.3.2 Chimeric Antigen Receptor Cell Therapy Market Drivers 2.3.3 Chimeric Antigen Receptor Cell Therapy Market Challenges 2.3.4 Chimeric Antigen Receptor Cell Therapy Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Chimeric Antigen Receptor Cell Therapy Players by Revenue 3.1.1 Global Top Chimeric Antigen Receptor Cell Therapy Players by Revenue (2017-2022) 3.1.2 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Players (2017-2022) 3.2 Global Chimeric Antigen Receptor Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Chimeric Antigen Receptor Cell Therapy Revenue 3.4 Global Chimeric Antigen Receptor Cell Therapy Market Concentration Ratio 3.4.1 Global Chimeric Antigen Receptor Cell Therapy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Chimeric Antigen Receptor Cell Therapy Revenue in 2021 3.5 Chimeric Antigen Receptor Cell Therapy Key Players Head office and Area Served 3.6 Key Players Chimeric Antigen Receptor Cell Therapy Product Solution and Service 3.7 Date of Enter into Chimeric Antigen Receptor Cell Therapy Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Chimeric Antigen Receptor Cell Therapy Breakdown Data by Type 4.1 Global Chimeric Antigen Receptor Cell Therapy Historic Market Size by Type (2017-2022) 4.2 Global Chimeric Antigen Receptor Cell Therapy Forecasted Market Size by Type (2023-2035) 5 Chimeric Antigen Receptor Cell Therapy Breakdown Data by Application 5.1 Global Chimeric Antigen Receptor Cell Therapy Historic Market Size by Application (2017-2022) 5.2 Global Chimeric Antigen Receptor Cell Therapy Forecasted Market Size by Application (2023-2035) 6 North America 6.1 North America Chimeric Antigen Receptor Cell Therapy Market Size (2017-2035) 6.2 North America Chimeric Antigen Receptor Cell Therapy Market Size by Type 6.2.1 North America Chimeric Antigen Receptor Cell Therapy Market Size by Type (2017-2022) 6.2.2 North America Chimeric Antigen Receptor Cell Therapy Market Size by Type (2023-2035) 6.2.3 North America Chimeric Antigen Receptor Cell Therapy Market Share by Type (2017-2035) 6.3 North America Chimeric Antigen Receptor Cell Therapy Market Size by Application 6.3.1 North America Chimeric Antigen Receptor Cell Therapy Market Size by Application (2017-2022) 6.3.2 North America Chimeric Antigen Receptor Cell Therapy Market Size by Application (2023-2035) 6.3.3 North America Chimeric Antigen Receptor Cell Therapy Market Share by Application (2017-2035) 6.4 North America Chimeric Antigen Receptor Cell Therapy Market Size by Country 6.4.1 North America Chimeric Antigen Receptor Cell Therapy Market Size by Country (2017-2022) 6.4.2 North America Chimeric Antigen Receptor Cell Therapy Market Size by Country (2023-2035) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Chimeric Antigen Receptor Cell Therapy Market Size (2017-2035) 7.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Type 7.2.1 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Type (2017-2022) 7.2.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Type (2023-2035) 7.2.3 Europe Chimeric Antigen Receptor Cell Therapy Market Share by Type (2017-2035) 7.3 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Application 7.3.1 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Application (2017-2022) 7.3.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Application (2023-2035) 7.3.3 Europe Chimeric Antigen Receptor Cell Therapy Market Share by Application (2017-2035) 7.4 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Country 7.4.1 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Country (2017-2022) 7.4.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Country (2023-2035) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size (2017-2035) 8.2 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Type 8.2.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Type (2023-2035) 8.2.3 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Share by Type (2017-2035) 8.3 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Application 8.3.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Application (2023-2035) 8.3.3 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Share by Application (2017-2035) 8.4 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Region 8.4.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Region (2023-2035) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Chimeric Antigen Receptor Cell Therapy Market Size (2017-2035) 9.2 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Type 9.2.1 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Type (2017-2022) 9.2.2 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Type (2023-2035) 9.2.3 Latin America Chimeric Antigen Receptor Cell Therapy Market Share by Type (2017-2035) 9.3 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Application 9.3.1 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Application (2017-2022) 9.3.2 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Application (2023-2035) 9.3.3 Latin America Chimeric Antigen Receptor Cell Therapy Market Share by Application (2017-2035) 9.4 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Country 9.4.1 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Country (2017-2022) 9.4.2 Latin America Chimeric Antigen Receptor Cell Therapy Market Size by Country (2023-2035) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size (2017-2035) 10.2 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Type 10.2.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Type (2023-2035) 10.2.3 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Share by Type (2017-2035) 10.3 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Application 10.3.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Application (2023-2035) 10.3.3 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Share by Application (2017-2035) 10.4 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Country 10.4.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Country (2023-2035) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Amgen Inc 11.1.1 Amgen Inc Company Details 11.1.2 Amgen Inc Business Overview 11.1.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.1.4 Amgen Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.1.5 Amgen Inc Recent Developments 11.2 Autolus Therapeutics Plc 11.2.1 Autolus Therapeutics Plc Company Details 11.2.2 Autolus Therapeutics Plc Business Overview 11.2.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Introduction 11.2.4 Autolus Therapeutics Plc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.2.5 Autolus Therapeutics Plc Recent Developments 11.3 Beijing Immunochina Medical Science & Technology Co Ltd 11.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Company Details 11.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Business Overview 11.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments 11.4 Bellicum Pharmaceuticals Inc 11.4.1 Bellicum Pharmaceuticals Inc Company Details 11.4.2 Bellicum Pharmaceuticals Inc Business Overview 11.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.4.4 Bellicum Pharmaceuticals Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.4.5 Bellicum Pharmaceuticals Inc Recent Developments 11.5 Bristol-Myers Squibb Co 11.5.1 Bristol-Myers Squibb Co Company Details 11.5.2 Bristol-Myers Squibb Co Business Overview 11.5.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Introduction 11.5.4 Bristol-Myers Squibb Co Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.5.5 Bristol-Myers Squibb Co Recent Developments 11.6 bluebird bio Inc 11.6.1 bluebird bio Inc Company Details 11.6.2 bluebird bio Inc Business Overview 11.6.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.6.4 bluebird bio Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.6.5 bluebird bio Inc Recent Developments 11.7 CARsgen Therapeutics Ltd 11.7.1 CARsgen Therapeutics Ltd Company Details 11.7.2 CARsgen Therapeutics Ltd Business Overview 11.7.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.7.4 CARsgen Therapeutics Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.7.5 CARsgen Therapeutics Ltd Recent Developments 11.8 Celgene Corp 11.8.1 Celgene Corp Company Details 11.8.2 Celgene Corp Business Overview 11.8.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Introduction 11.8.4 Celgene Corp Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.8.5 Celgene Corp Recent Developments 11.9 Cell Medica Ltd 11.9.1 Cell Medica Ltd Company Details 11.9.2 Cell Medica Ltd Business Overview 11.9.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.9.4 Cell Medica Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.9.5 Cell Medica Ltd Recent Developments 11.10 Cellular Biomedicine Group Inc 11.10.1 Cellular Biomedicine Group Inc Company Details 11.10.2 Cellular Biomedicine Group Inc Business Overview 11.10.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.10.4 Cellular Biomedicine Group Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.10.5 Cellular Biomedicine Group Inc Recent Developments 11.11 Celularity Inc 11.11.1 Celularity Inc Company Details 11.11.2 Celularity Inc Business Overview 11.11.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.11.4 Celularity Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.11.5 Celularity Inc Recent Developments 11.12 Celyad SA 11.12.1 Celyad SA Company Details 11.12.2 Celyad SA Business Overview 11.12.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Introduction 11.12.4 Celyad SA Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.12.5 Celyad SA Recent Developments 11.13 Daiichi Sankyo Co Ltd 11.13.1 Daiichi Sankyo Co Ltd Company Details 11.13.2 Daiichi Sankyo Co Ltd Business Overview 11.13.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.13.4 Daiichi Sankyo Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.13.5 Daiichi Sankyo Co Ltd Recent Developments 11.14 Fosun Pharmaceutical AG 11.14.1 Fosun Pharmaceutical AG Company Details 11.14.2 Fosun Pharmaceutical AG Business Overview 11.14.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Introduction 11.14.4 Fosun Pharmaceutical AG Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.14.5 Fosun Pharmaceutical AG Recent Developments 11.15 Gilead Sciences Inc 11.15.1 Gilead Sciences Inc Company Details 11.15.2 Gilead Sciences Inc Business Overview 11.15.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.15.4 Gilead Sciences Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.15.5 Gilead Sciences Inc Recent Developments 11.16 Guangzhou Anjie Biomedical Technology Co Ltd 11.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Company Details 11.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Business Overview 11.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments 11.17 Hangzhou Converd Co Ltd 11.17.1 Hangzhou Converd Co Ltd Company Details 11.17.2 Hangzhou Converd Co Ltd Business Overview 11.17.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.17.4 Hangzhou Converd Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.17.5 Hangzhou Converd Co Ltd Recent Developments 11.18 Hebei Senlang Biotechnology Inc Ltd 11.18.1 Hebei Senlang Biotechnology Inc Ltd Company Details 11.18.2 Hebei Senlang Biotechnology Inc Ltd Business Overview 11.18.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.18.4 Hebei Senlang Biotechnology Inc Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Developments 11.19 HRAIN Biotechnology Co Ltd 11.19.1 HRAIN Biotechnology Co Ltd Company Details 11.19.2 HRAIN Biotechnology Co Ltd Business Overview 11.19.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.19.4 HRAIN Biotechnology Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.19.5 HRAIN Biotechnology Co Ltd Recent Developments 11.20 Juno Therapeutics Inc 11.20.1 Juno Therapeutics Inc Company Details 11.20.2 Juno Therapeutics Inc Business Overview 11.20.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.20.4 Juno Therapeutics Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.20.5 Juno Therapeutics Inc Recent Developments 11.21 Kite Pharma Inc 11.21.1 Kite Pharma Inc Company Details 11.21.2 Kite Pharma Inc Business Overview 11.21.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.21.4 Kite Pharma Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.21.5 Kite Pharma Inc Recent Developments 11.22 Nanjing Legend Biotech Co Ltd 11.22.1 Nanjing Legend Biotech Co Ltd Company Details 11.22.2 Nanjing Legend Biotech Co Ltd Business Overview 11.22.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.22.4 Nanjing Legend Biotech Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.22.5 Nanjing Legend Biotech Co Ltd Recent Developments 11.23 NantKwest Inc 11.23.1 NantKwest Inc Company Details 11.23.2 NantKwest Inc Business Overview 11.23.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.23.4 NantKwest Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.23.5 NantKwest Inc Recent Developments 11.24 Nkarta Inc 11.24.1 Nkarta Inc Company Details 11.24.2 Nkarta Inc Business Overview 11.24.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.24.4 Nkarta Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.24.5 Nkarta Inc Recent Developments 11.25 Novartis AG 11.25.1 Novartis AG Company Details 11.25.2 Novartis AG Business Overview 11.25.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Introduction 11.25.4 Novartis AG Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.25.5 Novartis AG Recent Developments 11.26 Ono Pharmaceutical Co Ltd 11.26.1 Ono Pharmaceutical Co Ltd Company Details 11.26.2 Ono Pharmaceutical Co Ltd Business Overview 11.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.26.4 Ono Pharmaceutical Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.26.5 Ono Pharmaceutical Co Ltd Recent Developments 11.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd 11.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details 11.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Business Overview 11.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Introduction 11.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments 11.28 Sorrento Therapeutics Inc 11.28.1 Sorrento Therapeutics Inc Company Details 11.28.2 Sorrento Therapeutics Inc Business Overview 11.28.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.28.4 Sorrento Therapeutics Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.28.5 Sorrento Therapeutics Inc Recent Developments 11.29 Takara Bio Inc 11.29.1 Takara Bio Inc Company Details 11.29.2 Takara Bio Inc Business Overview 11.29.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Introduction 11.29.4 Takara Bio Inc Revenue in Chimeric Antigen Receptor Cell Therapy Business (2017-2022) 11.29.5 Takara Bio Inc Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Browse Related Pages

Global Chimeric Antigen Receptor Cell Therapy Market Companies More Medical Care Reports

Have Questions?

Speak to our analysts to get answers to your queries.

Inquiry Before Buying
TESTIMONIALS

What our clients say about us ?

★★★★★

"The standard report was strong from the beginning. What truly added value was the collaboration with the researchers we could openly discuss market insights and request additional data and analyses over several rounds."

Client

Michael Heidecker

Founder and Managing Director

★★★★★

"Extent Research delivered exactly what we needed reliable data, competitive pricing, and outstanding support. Their team was responsive, collaborative, and enhanced the report with custom insights every step of the way."

Client

Dr. Bernd Binder

Product Manager

★★★★★

"Super quick and helpful support even during the holidays! I really appreciated the effort. The report quality was excellent, with clear details and great insights that helped me understand the progress easily. Thank you so much!"

Client

Ryoko Tanaka

Head of Planning Dept

Top Brands That Trust Us

×
Julie
View Profile

Julie

Head of Research & Multidisciplinary Strategist

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly balances analytical rigor with sharp business acumen. Throughout her impressive career, she has evolved from a dedicated research analyst into a visionary leader who specializes in decoding complex market dynamics, analyzing competitive landscapes, and identifying emerging global trends. Her primary mission is to transform raw, intricate data into forward-looking strategies and actionable intelligence that empower stakeholders to make highly informed, strategic decisions.

Data provided by Extent Research. Source: https://www.extentresearch.com/chimeric-antigen-receptor-cell-therapy-market

Under her expert leadership, the team at Extent Research consistently delivers top-tier insights across an incredibly diverse array of international sectors. Whenever she oversees the development of a comprehensive Market Research Report, she ensures that it meticulously covers the specific nuances of the client’s target industry. Her multidisciplinary approach allows her to seamlessly integrate economic indicators and industry intelligence across vast domains. Her remarkable portfolio of sector expertise spans foundational global industries like Agriculture, Chemical & Material, Machinery & Equipment, Automobile & Transportation, Energy & Power, and Aerospace and Defense. Furthermore, she provides critical strategic oversight in fast-paced consumer and tech markets, including Consumer Goods, Food & Beverages, Packaging, Electronics & Semiconductor, Internet & Communication, New Technology, and Service & Software. Her expansive analytical reach also deeply penetrates life sciences and wellness fields, delivering precise data for Medical Care, Medical Devices & Consumables, and Pharma & Healthcare.

Recognized industry-wide for designing highly effective, customized research methodologies, Julie brings a uniquely visionary approach to strategic consulting. She integrates deep data analysis with a macro-economic perspective, ensuring that every piece of industry intelligence is fully utilized to drive meaningful business transformations. Her exceptional ability to work fluidly across so many complex sectors gives her clients a distinct competitive advantage in highly saturated markets. Ultimately, Julie Jayne’s leadership is the driving force behind Extent Research’s unwavering commitment to delivering elite, actionable insights, proving her to be an invaluable asset to organizations looking to navigate the future of global commerce.

Domain Assigned: Multiple Sectors
×
Priya M
View Profile

Priya M

Vice President

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives with highly tailored, research-backed solutions. She brings a wealth of strategic experience to the table, ensuring that decision-makers are armed with the precise intelligence required to navigate highly competitive and rapidly evolving global markets.

Data provided by Extent Research. Source: https://www.extentresearch.com/chimeric-antigen-receptor-cell-therapy-market

Currently serving as a foundational pillar at Extent Research, Priya operates as the primary driving force behind the firm’s unwavering commitment to analytical excellence. She acts as the vital linchpin within the organization’s comprehensive research pipeline, meticulously reviewing and vetting all incoming data and outgoing insights. Her rigorous quality control guarantees that every single Market Research Report published meets elite industry standards for accuracy, relevance, and clarity. Through her steadfast dedication to precision, she ensures that clients receive reliable, transformative intelligence tailored directly to their long-term strategic needs.

Cross-Industry Expertise

Priya’s exceptional analytical prowess is not confined to a single niche. Rather, she possesses a broad, cross-industry expertise that allows her to expertly decode intricate market shifts and uncover hidden economic patterns. Her ability to synthesize complex technological innovations and sector-specific developments allows her to offer fresh, multifaceted perspectives. She expertly oversees data, forecasts, and emerging trends across an expansive spectrum of global industries, including:

  • Aerospace and Defense
  • Agriculture
  • Automobile & Transportation
  • Chemical & Material
  • Consumer Goods
  • Electronics & Semiconductor
  • Energy & Power
  • Food & Beverages
  • Internet & Communication
  • Machinery & Equipment
  • Medical Care
  • Medical Devices & Consumables
  • New Technology
  • Packaging
  • Pharma & Healthcare
  • Service & Software

Transforming Data into Strategy

By analyzing cross-domain developments across these diverse sectors, Priya effortlessly translates highly technical and complex datasets into digestible, actionable intelligence. She does not merely report static facts; she actively brings the intricate world of market intelligence to life, making it highly engaging and educational for investors, seasoned professionals, and corporate leaders alike.

Her exceptional attention to detail and her innate ability to forecast tomorrow’s emerging innovations keep her and her global clientele consistently one step ahead of the curve. Ultimately, Priya M’s unwavering dedication to precision, combined with her forward-thinking methodology, makes her an indispensable asset to the industry. She guarantees that every piece of strategic advice delivered is backed by rigorous, world-class research.

Domain Assigned: Multiple Sectors